Arvinas/$ARVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Ticker
$ARVN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
430
ISIN
US04335A1051
Website
Arvinas Metrics
BasicAdvanced
$576M
-
-$0.65
2.32
-
Price and volume
Market cap
$576M
Beta
2.32
52-week high
$34.11
52-week low
$5.90
Average daily volume
2.1M
Financial strength
Current ratio
4.578
Quick ratio
4.499
Long term debt to equity
1.303
Total debt to equity
1.591
Profitability
EBITDA (TTM)
-91.4
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-10.92%
Operating margin (TTM)
-22.37%
Effective tax rate (TTM)
-1.53%
Revenue per employee (TTM)
$990,000
Management effectiveness
Return on assets (TTM)
-5.39%
Return on equity (TTM)
-7.34%
Valuation
Price to revenue (TTM)
1.333
Price to book
0.87
Price to tangible book (TTM)
0.87
Price to free cash flow (TTM)
-2.25
Free cash flow yield (TTM)
-44.44%
Free cash flow per share (TTM)
-350.62%
Growth
Revenue change (TTM)
498.74%
Earnings per share change (TTM)
-89.06%
3-year revenue growth (CAGR)
78.87%
3-year earnings per share growth (CAGR)
-46.33%
What the Analysts think about Arvinas
Analyst ratings (Buy, Hold, Sell) for Arvinas stock.
Bulls say / Bears say
Arvinas, in collaboration with Pfizer, reported that their experimental breast cancer drug, vepdegestrant, significantly outperformed AstraZeneca's Faslodex in delaying disease progression, extending progression-free survival to five months compared to Faslodex's two months. (reuters.com)
The company reported a substantial increase in revenue for the first quarter of 2025, reaching $188.8 million, a significant rise from $25.3 million in the same period of 2024, indicating strong financial growth. (biospace.com)
Arvinas maintains a robust cash position, with cash, cash equivalents, and marketable securities totaling $979.7 million as of March 31, 2025, providing a solid foundation for future operations and research initiatives. (biospace.com)
Despite the promising results of vepdegestrant, Arvinas announced it will halt two other late-stage studies of the drug, potentially limiting its pipeline expansion. (reuters.com)
The company's Altman Z-score is 0.12, placing it in the distress zone and indicating a potential risk of bankruptcy within the next two years. (gurufocus.com)
Arvinas reported a net loss of $49.2 million for the third quarter of 2024, reflecting ongoing financial challenges despite revenue growth. (sec.gov)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Arvinas Financial Performance
Revenues and expenses
Arvinas Earnings Performance
Company profitability
Arvinas News
AllArticlesVideos
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
GlobeNewsWire·2 days ago
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
GlobeNewsWire·4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arvinas stock?
Arvinas (ARVN) has a market cap of $576M as of July 11, 2025.
What is the P/E ratio for Arvinas stock?
The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of July 11, 2025.
Does Arvinas stock pay dividends?
No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Arvinas dividend payment date?
Arvinas (ARVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Arvinas?
Arvinas (ARVN) has a beta rating of 2.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.